J418G Insurance Policy Changes

Non-Preferred Filgrastim Products (Revised)

Humana has implemented a revised prior authorization policy for non-preferred filgrastim products (Neupogen, Nypozi, Releuko, Filkri) effective January 1, 2026, across Kentucky and South Carolina Medicaid plans. All non-preferred filgrastim products now require prior authorization, and approval is contingent upon documented previous treatment failure or intolerance to both preferred alternatives (Zarxio and Nivestym). This policy significantly restricts access to non-preferred filgrastim formulations across 12 distinct clinical indications.